What Myosin Therapeutics does

Myosin Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2020 as a spinout from The Wertheim UF Scripps Institute (formerly Scripps Research, Florida) by neuroscientist Courtney Miller and medicinal chemists Patrick Griffin and Theodore Kamenecka. The company is developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, with a primary focus on dual non-muscle myosin IIA/IIB (NMIIA/IIB) inhibitors. The lead asset, MT-125, is an orally bioavailable, brain-penetrant dual NMIIA/IIB inhibitor being evaluated in the Phase 1/2 STAR-GBM trial in newly diagnosed, MGMT unmethylated glioblastoma in collaboration with Mayo Clinic. A second core program, MT-110, targets NMII to reduce motivation for stimulants without impairing natural rewards and is advancing toward a Phase 1 trial for methamphetamine use disorder, with potential expansion to cocaine, alcohol, and opioid use disorders. Two preclinical programs (MT-228 in non-orphan oncology, MT-134 in musculoskeletal indications) extend the platform.

Name

Myosin Therapeutics

Legal name

Myosin Therapeutics Inc.

Website

https://myosintherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neuro-Oncology (HLAKAFAH)

Keywords

• Small molecule therapeutics
• Oncology drug development
• CNS disorder treatment
• Clinical-stage biotechnology
• Molecular nanomotor inhibitors

Headquarters

HQ city

Jupiter

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels8 records

Core offering

Myosin Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, specifically non-muscle myosin IIA and IIB (NMIIA/IIB) inhibitors. The company is advancing MT-125 (a brain-penetrant, orally available dual NMIIA/IIB inhibitor) through a Phase 1/2 STAR-GBM clinical trial for newly diagnosed glioblastoma at Mayo Clinic, with MT-110 advancing toward a Phase 1 trial for methamphetamine use disorder and additional preclinical candidates MT-228 (non-orphan oncology) and MT-134 (musculoskeletal) in its pipeline.

Product overview

Myosin Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins. The company's portfolio consists of a platform technology and multiple drug candidates: MT-125 (dual NMIIA/IIB inhibitor for glioblastoma and other treatment-resistant cancers), MT-110 (for methamphetamine and other substance use disorders), MT-228 (for non-orphan oncology), and MT-134 (for undisclosed musculoskeletal indication). MT-125 is the lead clinical program in Phase 1/2 trials for newly diagnosed glioblastoma, while MT-110 is advancing toward Phase 1 trials for methamphetamine use disorder.

Differentiator

Problem solved

Functional benefit

Products and services

• MT-125 MT-125 is a brain-penetrant, orally-available first-in-class dual inhibitor of non-muscle myosin IIA and IIB (NMIIA/IIB) being developed for oncology. It targets the cellular mechanics of tumor cells to simultaneously prevent tumor invasion and proliferation while activating tumor cell stress responses leading to their elimination. It is administered with standard radiotherapy in the STAR-GBM trial for newly diagnosed, IDH wildtype, MGMT unmethylated glioblastoma, and is also being evaluated for acute myeloid leukemia and pancreatic adenocarcinoma.
• MT-110 MT-110 is a small molecule that targets molecular nanomotor proteins to reduce motivation for methamphetamine and other stimulants and prevent relapses without impacting natural rewards. It is being developed for methamphetamine use disorder, cocaine use disorder, alcohol use disorder, and opioid use disorder. The program has NIDA/NIH grant support and is advancing toward a Phase 1 clinical trial.
• MT-228 MT-228 is an NMIIA/IIB small molecule inhibitor with unique characteristics being pursued for non-orphan oncology indications. It is currently in preclinical development.
• MT-134 MT-134 is a small molecule therapeutic candidate with an undisclosed musculoskeletal indication. It is currently in preclinical development.

Quantifiable outcome

• Phase 1/2 STAR-GBM trial initiated May 2026 with first patient dosed
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core, significant and minor.

• Mayo CliniccoreStrategic or Co-development Partner · 19 May 2026Collaboration for STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in newly diagnosed glioblastoma. Trial conducted across all three Mayo Clinic clinical research units in Minnesota, Florida (Jacksonville), and Arizona (Scottsdale/Phoenix). Mayo Clinic investigators including Dr. Steven Rosenfeld contributed to preclinical research and serve as principal investigators.
• MRI GlobalsignificantStrategic or Co-development PartnerContract research organization providing GMP manufacturing services. Partnered with Myosin for GMP manufacturing of MT-110 to support IND submission and Phase 1 clinical trials. MRI Global has extensive experience in GMP manufacturing with focus on safety, quality, and regulatory compliance.
• NYUminorStrategic or Co-development PartnerAcademic partner listed in company investor and partner logos section.
• Yale UniversityminorStrategic or Co-development PartnerAcademic partner listed in company investor and partner logos section.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Axsome Therapeutics: Commercial CNS-focused biotech developing small molecule therapies for treatment-resistant CNS disorders. Comparable in its small molecule CNS drug development focus and clinical-stage execution, though Axsome has reached commercialization while Myosin is pre-revenue.
• Kazia Therapeutics: Clinical-stage oncology biotech developing paxalisib (PI3K/mTOR inhibitor) for newly diagnosed and recurrent glioblastoma. Directly comparable to Myosin's MT-125 in targeting the GBM indication with a small molecule mechanism and Orphan/Fast Track regulatory positioning.
• Praxis Precision Medicines: Clinical-stage CNS biotech developing small molecule therapies for neurological and psychiatric disorders with high unmet need. Comparable in targeting underserved CNS indications with first-in-class small molecule mechanisms, with similar stage and capital profile to Myosin.
• Diffusion Pharmaceuticals: Clinical-stage biopharma developing trans sodium crocetinate (TSC) for hypoxic solid tumors including GBM. Comparable small molecule mechanism, GBM lead indication, and clinical-stage development profile targeting treatment-resistant solid tumors.
• Black Diamond Therapeutics: Clinical-stage precision oncology biotech developing small molecule allosteric modulators against novel protein targets. Comparable in its focus on first-in-class small molecule discovery against previously undruggable targets, though with a broader solid tumor pipeline than Myosin's neuro-oncology focus.
• Kintara Therapeutics: Clinical-stage oncology company developing VAL-083 (dianhydrogalactitol) for newly diagnosed and recurrent glioblastoma, with FDA Orphan Drug and Fast Track designations. Closely comparable lead indication, regulatory strategy, and clinical-stage profile to Myosin Therapeutics.

Broad incumbents

• Tango Therapeutics: Clinical-stage oncology biotech developing small molecule precision therapeutics against novel synthetic lethal targets. Comparable as a publicly traded small molecule oncology platform with multiple first-in-class programs, though at a more advanced stage and broader pipeline.
• Indivior: Commercial CNS company specializing in treatments for substance use disorders, including opioid and stimulant addiction. Comparable in targeting the same addressable patient population as MT-110, though Indivior is established and focused on opioid dependence specifically.
• Revolution Medicines: Late-stage precision oncology company developing novel small molecule inhibitors targeting difficult-to-drug cancer targets. Comparable in pioneering first-in-class small molecules against previously undruggable protein classes, though at a substantially more advanced clinical and market scale.
• Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapies for neurodegenerative diseases with CNS penetrance. Comparable in its emphasis on brain-penetrant small molecules for CNS indications, though Denali operates at significantly greater scale and broader CNS scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/MyosinTx
• LinkedInlinkedin.com/company/myosin-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myosin Therapeutics